The management of hereditary transthyretin-mediated amyloidosis (hATTR) is important in the medical community, as patients suffer from serious associated symptoms, such as polyneuropathy, which calls for safe and efficacious agents to help slow the progression of the disease. This activity covers the proper use of inotersen contributes to the management of subsequent disease manifestations, including the importance of utilizing such targeted therapy, which, in turn, augments the patient treatment strategy.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/137855
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Adult Cardiac, Cardiothoracic, Cardiovascular, Cardiovascular Disease, Critical Care Medicine, General Surgery, Internal Medicine, Molecular Genetic Pathology, Rheumatology
Subscribe
Login
0 Comments
Oldest